NYSE$ALUR
Allurion Technologies Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Allurion's third quarter results for 2024 were reported, showing a decrease in revenue due to de-stocking, macroeconomic headwinds, and a temporary suspension of sales in France.
Allurion Technologies reported a revenue of $5.4 million for Q3 2024, which includes a $1.2 million reduction for product recalled from France. The company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year. A business restructuring plan is expected to reduce operating expenses by 50% in 2025 and achieve profitability by the end of 2025.
- Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter
- AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year
- Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year
- Initiated business restructuring which is expected to reduce operating expense by 50% in 2025 and achieve profitability by end of 2025
Headline financials
Revenue & EPS history
Allurion · Revenue · Quarterly
$5.37M
Forward guidance
The Company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+1.5%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+63.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+47.1%
Q4 2025
Best reaction
-43.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.0% | +25.1% | +1467.3% | |
| Q4 2025 | +47.1% | +35.3% | +47.1% | |
| Q3 2025 | +1.4% | -6.0% | +12.1% | |
| Q2 2025 | +0.8% | -8.1% | -16.3% | |
| Q1 2025 | +25.1% | +29.7% | +5.1% | |
| Q4 2024 | +0.3% | +3.2% | -22.8% | |
| Q3 2024 | -43.7% | -46.2% | -51.3% | |
| Q2 2024 | -12.7% | -17.0% | -20.8% | |
| Q1 2024 | -1.0% | -8.8% | -28.4% | |
| Q4 2023 | -11.9% | -11.0% | -5.2% | |
| Q3 2022 | +2.4% | +0.7% | -18.7% | |
| Q3 2023 | +6.7% | +2.4% | -15.9% | |
| Q2 2022 | -2.3% | +3.8% | -3.6% | |
| Q1 2023 | -2.3% | +3.8% | -3.6% | |
| Q2 2023 | -2.3% | +3.8% | -3.6% | |
| Q4 2022 | -2.3% | +3.8% | -3.6% | |
| Q1 2022 | +0.0% | +0.2% | +0.3% | |
| Q4 2021 | +0.1% | +0.3% | -0.1% | |
| Q3 2021 | -0.2% | +0.0% | +0.0% | |
| Q2 2021 | -0.1% | -0.5% | -1.3% | |
| Q1 2021 | +0.9% | +1.0% | +2.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro